Loader
Loading Pathway...
ATP synthase subunit beta, mitochondrial ATP synthase subunit alpha, mitochondrial ADP/ATP translocase 1 HMG-CoA reductase Mevalonate kinase Phosphomevalonate kinase Farnesyl pyrophosphate synthase Farnesyl pyrophosphate synthase Squalene synthase Diphosphomevalonate decarboxylase Geranylgeranyl pyrophosphate synthase Hydroxymethylglutaryl- CoA synthase, cytoplasmic Acetyl-CoA acetyltransferase, mitochondrial ATP synthase lipid-binding protein, mitochondrial ATP synthase subunit a ATP synthase subunit b, mitochondrial ATP synthase subunit delta, mitochondrial ATP synthase subunit epsilon, mitochondrial ATP synthase subunit gamma, mitochondrial Tiludronate ATP ADP ADP ATP ADP ATP Tiludronate Tiludronate Tiludronate Tiludronate Tiludronate 3-Hydroxy-3-methylglutaryl-CoA NADPH H+ NADP CoA Mevalonate ATP Mevalonate-5P ADP ATP Mevalonate-5PP ADP Isopentenyl-PP Dimethylallylpyrophosphate PPi Geranyl-PP Isopentenyl pyrophosphate Farnesyl pyrophosphate PPi H+ NADPH PPi NADP Squalene Cholesterol ATP ADP Pi CO2 Isopentenyl pyrophosphate Geranylgeranyl-PP PPi Acetyl-CoA H2O Acetoacetyl-CoA CoA CoA H+ H+ Magnesium Magnesium Magnesium Magnesium Osteoclast Cytosol Mevalonate Pathway Tiludronate enters the cell through endocytosis. The endocytic vesicles are acidified and the tiludronate is released into the cytosol. Inner Membrane Outer Membrane Mitochondrial Matrix Tiludronate structure allows it to become an ATP analogue that is nonfunctional disrupting osteoclast survival Bone Loss Tiludronate is administered orally and travels to the bone Tiludronate acts to counteract osteoclast activity and reduce bone degradation
Mitochondria ATP5B ATP5A1 SLC25A4 HMGCLL1 MVK PMVK FDPS FDPS FDFT1 MVD GGPS1 HMGCS1 ACAT1 ATP5G2 MT-ATP6 ATP5F1 ATP5D ATP5E ATP5C1 Tiludronate Adenosine triphosphate Adenosine diphosphate Adenosine diphosphate Adenosine triphosphate Adenosine diphosphate Adenosine triphosphate Tiludronate Tiludronate Tiludronate Tiludronate Tiludronate 3-Hydroxy-3- methylglutaryl- CoA NADPH Hydrogen Ion NADP Coenzyme A Mevalonate Adenosine triphosphate Mevalonate-5P Adenosine diphosphate Adenosine triphosphate Mevalonate-5PP Adenosine diphosphate Isopentenyl-PP Dimethylallylpyrophosphate Pyrophosphate Geranyl-PP Isopentenyl pyrophosphate Farnesyl pyrophosphate Pyrophosphate Hydrogen Ion NADPH Pyrophosphate NADP Squalene Cholesterol Adenosine triphosphate Adenosine diphosphate Phosphate Carbon dioxide Isopentenyl pyrophosphate Geranylgeranyl- PP Pyrophosphate Acetyl-CoA Water Acetoacetyl-CoA Coenzyme A Coenzyme A Hydrogen Ion Hydrogen Ion
ATP5B ATP5A1 SLC25A4 HMGCLL1 MVK PMVK FDPS FDPS FDFT1 MVD GGPS1 HMGCS1 ACAT1 ATP5G2 MT-ATP6 ATP5F1 ATP5D ATP5E ATP5C1 Tiludro ATP ADP ADP ATP ADP ATP Tiludro Tiludro Tiludro Tiludro Tiludro HMG-CoA NADPH H+ NADP CoA Meval ATP Meva-5P ADP ATP Mev-5PP ADP Isop-PP Ipe PPi Gryl-PP IsopPyr FarPP PPi H+ NADPH PPi NADP Squalen Lanol ATP ADP Pi CO2 IsopPyr GGDP PPi Ac-CoA H2O ActaCoA CoA CoA H+ H+ Mg2+ Mg2+ Mg2+ Mg2+ Osteoclast Cytosol Mevalonate Pathway Tiludronate enters the cell through endocytosis. The endocytic vesicles are acidified and the tiludronate is released into the cytosol. Inner Membrane Outer Membrane Mitochondrial Matrix Tiludronate structure allows it to become an ATP analogue that is nonfunctional disrupting osteoclast survival Bone Loss Tiludronate is administered orally and travels to the bone Tiludronate acts to counteract osteoclast activity and reduce bone degradation
Mitochondria ATP5B ATP5A1 SLC25A4 HMGCLL1 MVK PMVK FDPS FDPS FDFT1 MVD GGPS1 HMGCS1 ACAT1 ATP5G2 MT-ATP6 ATP5F1 ATP5D ATP5E ATP5C1 Tiludro ATP ADP ADP ATP ADP ATP Tiludro Tiludro Tiludro Tiludro Tiludro HMG-CoA NADPH H+ NADP CoA Meval ATP Meva-5P ADP ATP Mev-5PP ADP Isop-PP Ipe Ppi Gryl-PP IsopPyr FarPP Ppi H+ NADPH Ppi NADP Squalen Lanol ATP ADP Pi CO2 IsopPyr GGDP Ppi Ac-CoA H2O ActaCoA CoA CoA H+ H+